NTLA
Intellia Therapeutics Inc
13.10$
+3.7%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 19.1% | – | 8.7% | 37.4% | 1,198.3% | 907.9% | – | 565.3% | 572.8% | 26.1% | 14.6% | – | – | |
| 80.9% | – | 91.3% | 62.6% | -1,098.3% | -807.9% | 100.0% | -465.3% | -472.8% | 73.9% | 85.4% | 100.0% | -46.5% | |
| 948.1% | – | 377.9% | 1,604.3% | 1,354.2% | 907.9% | 652.1% | 681.2% | 687.5% | 385.2% | 536.5% | 1,078.4% | 582.7% | |
| 245.2% | – | 107.5% | 457.0% | 334.8% | 252.0% | 174.5% | 191.0% | 221.4% | 143.7% | 231.5% | 493.9% | 229.0% | |
| 1,174.2% | – | 485.3% | 2,061.2% | 490.7% | 252.0% | 826.6% | 306.8% | 336.0% | 502.7% | 753.4% | 1,572.3% | 665.2% | |
| -1,093.3% | – | -394.0% | -1,998.6% | -1,589.0% | -1,059.9% | -726.6% | -772.2% | -808.9% | -428.9% | -668.1% | -1,472.3% | -711.7% | |
| -1,019.2% | – | -371.3% | -2,112.6% | -1,489.5% | -1,001.2% | -687.6% | -710.8% | -735.2% | -416.2% | -639.5% | -1,392.3% | -672.2% | |
| -125.3% | – | 8.5% | – | – | – | – | – | – | – | – | – | – | |
| -1,019.2% | – | -371.3% | -2,112.6% | -1,489.5% | -1,001.2% | -687.6% | -710.8% | -735.2% | -416.2% | -639.5% | -1,392.3% | -672.2% | |
| -1,000.1% | – | -362.6% | -2,075.3% | -1,460.9% | -981.3% | -672.6% | -693.4% | -699.4% | -414.5% | -624.9% | -1,365.1% | -656.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.